A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

The patient is pregnant or nursing (lactating) women, where pregnancy is defined as the state of the female after conception and until the termination of gestation, confirmed by a positive urine or serum pregnancy test.

The patient has any significant or organ abnormality as determined by the principal investigator/sub-investigator.

The patient has skin abnormalities/irritations at the potential injection site (right or left deltoid) as determined by the Principal Investigator/clinical Sub-Investigator.

The patient has a medical or surgical condition that might interfere with the absorption, metabolism, or excretion of paliperidone.

The patient has known allergy to the Paliperidone Palmitate or to any ingredient in the preparation.

The patient has a history of hypersensitivity to heparin.

The patient intended to significantly change the smoking habits during the trial (i.e. planned cessation or start of smoking career).

The patient will consume alcohol or caffeine or related xanthine containing foods or beverages for 48 hours prior to each dosing.

The patient will consume grapefruit or pomelo-containing beverages and foods within 7 days prior to each dosing.

The patient has a history of or current compulsive abuse of alcohol (more than 10 drinks weekly) or regular exposure to other substance of abuse.

The patient is on a special diet (for example the patient is a vegetarian), or dieting (on a weight lowering plan) during the month before the study.

The patient participated in a comparative bioavailability/ bioequivalence study within the last 90 days before first dose of period I.

The patient participated in a clinical study within the last 90 days before first dose of period I.

The patient donated blood or any of its constituents (1 unit or 350 ml) within the last 90 days before first dose of period I.

The patient has positive testing for HIV I \& II and/or Hepatitis B and/or Hepatitis C using ELISA method.

The patient has positive test for illicit drugs or alcohol before any dose.

The patient is suffering from severe hepatic impairment.

The patient is suffering from renal impairment

Presence or history of clinically significant cardiovascular disease (especially known history of QT prolongation, congenital long QT syndrome, recent acute myocardial infarction, cardiac arrhythmias, or with uncompensated heart failure).

The patient is receiving medicinal products known to prolong the QT interval, e.g. class 1 Antiarrhythmics (e.g., quinidine, disopyramide, procainamide) and class III antiarrhythmics (e.g. amiodarone, sotalol), antihistamines, antipsychotics known to prolong QT interval, and antimalarials (e.g. mefloquine, quinine), tricyclic antidepressants (eg amitriptyline), tetracyclic antidepressants (eg maprotiline).

The patient is receiving centrally acting medicinal products e.g. anxiolytics, risperidone, opiates, etc. or alcohol

The patient is receiving drugs that induce orthostatic hypotension (e,g other antipsychotics, tricyclic).

The patient is receiving medicinal products known to lower the seizure threshold (e.g. phenothiazines or butyrophenones, tricyclics or SSRIs, tramadol, mefloquine, etc.)

The patient is receiving carbamazepine (causes decrease in mean steady state Cmax and AUC of Paliperidone)

The patient has current thoughts of suicide or violent tendencies at screening.

What this study is about